BioCryst Pharmaceuticals, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2023 | $303.2M | $-455.5M | $110.6M |
| FY2024 | $314.9M | $-475.9M | $104.7M |
| FY2025 | $0 | $-119.2M | $89.7M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2023 | $303.2M | $-455.5M | $110.6M |
| FY2024 | $314.9M | $-475.9M | $104.7M |
| FY2025 | $0 | $-119.2M | $89.7M |